ClinicalTrials.gov record
Completed Not applicable Interventional Results available

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT01048099

Public ClinicalTrials.gov record NCT01048099. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 30, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing

Study identification

NCT ID
NCT01048099
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
SCRI Development Innovations, LLC
Other
Enrollment
283 participants

Conditions and interventions

Conditions

Interventions

  • PRO Onc Assay and Treatment Procedure
  • Pertuzumab Drug
  • Trastuzumab Drug

Procedure · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2010
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014
Last update posted
Jan 28, 2016

2011 – 2014

United States locations

U.S. sites
7
U.S. states
5
U.S. cities
7
Facility City State ZIP Site status
Florida Cancer Specialists Fort Myers Florida 33916
Florida Cancer Specialists St. Petersburg Florida 33705
Oncology Hematology Care, Inc. Cincinnati Ohio 45242
Chattanooga Oncology Hematology Associates Chattanooga Tennessee 37404
Tennessee Oncology, PLLC Nashville Tennessee 37023
Center for Cancer and Blood Disorders Fort Worth Texas 76104
Virginia Cancer Institute Richmond Virginia 23230

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01048099, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 28, 2016 · Synced Apr 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01048099 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →